Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

Hermansky-Pudlak syndrome (HPS) consists of oculocutaneous albinism, a platelet storage pool deficiency and, in patients with HPS1 gene mutations, a progressive, fatal pulmonary fibrosis. We investigated the safety and efficacy of an antifibrotic agent, pirfenidone (800 mg, t.i.d.), in treating 21 adult Puerto Rican HPS patients, including 20 homozygous for the same HPS1 mutation. Patients were examined every 4 months for up to 44 months in a randomized, placebo-controlled trial, with rate of change in pulmonary function values as outcome parameters. Using the complete data set of 130 patient admissions, a repeated measures model showed that 11 pirfenidone-treated patients lost FVC at a rate 5% of predicted (similar to400 mL) per year slower than 10 placebo-treated patients (p = 0.001). A random coefficients model showed no significant difference. However, using data restricted to patients with an initial FVC > 50% of predicted, both models showed the pirfenidone group losing FVC (p < 0.022), FEV(1) (p < 0.0007), TLC (p < 0.001), and DLCO (p < 0.122) at a rate similar to8%/year slower than the placebo group. Clinical and laboratory side effects were similar in the two groups. Pirfenidone appears to slow the progression of pulmonary fibrosis in HPS patients who have significant residual lung function. (C) 2002 Elsevier Science (USA). All rights reserved.